XENE
Xenon Pharmaceuticals Inc
NASDAQ: XENE · HEALTHCARE · BIOTECHNOLOGY
$55.75
+2.24% today
Updated 2026-04-29
Market cap
$5.39B
P/E ratio
—
P/S ratio
718.38x
EPS (TTM)
$-4.36
Dividend yield
—
52W range
$28 – $64
Volume
1.5M
Xenon Pharmaceuticals Inc (XENE) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | $63.30M | $54.49M | $87.42M | $63.95M | $67.49M | $46.12M | $122.43M | $147.70M | $189.19M | $572.01M | $754.15M | $964.80M | $798.14M |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | — | $60.70M | $49.87M | $84.94M | $60.87M | $65.67M | $44.82M | $121.44M | $144.87M | $181.78M | $559.02M | $600.30M | $644.96M | $635.26M |
| Total liabilities | — | $50.68M | $30.37M | $14.64M | $2.92M | $3.59M | $10.19M | $19.13M | $55.72M | $17.83M | $21.97M | $32.65M | $36.88M | $43.24M |
| Current liabilities | — | $19.20M | $18.20M | $14.29M | $2.78M | $3.52M | $4.08M | $4.12M | $43.38M | $14.78M | $14.32M | $22.70M | $27.27M | $35.59M |
| Long-term debt | — | $1.67M | — | $0.00 | $0.00 | $0.00 | $6.10M | $15.01M | $10.89M | — | — | — | — | — |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | — | $-128.78M | $-116.75M | $-103.73M | $-119.69M | $-142.68M | $-173.39M | $-207.88M | $-249.66M | $-278.49M | $-357.37M | $-482.75M | $-665.14M | $-899.47M |
| Accounts receivable | — | $392000.00 | $440000.00 | $215000.00 | $315000.00 | $200000.00 | $438000.00 | $256000.00 | $813000.00 | $1.82M | $2.77M | $986000.00 | $874000.00 | $1.47M |
| Inventory | — | — | $1.00 | $1.00 | $-315000.00 | $1.00 | $1.00 | — | — | $-1.82M | $-2.77M | $-986000.00 | $1.00 | — |
| Goodwill | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |